Survodutide is a next-generation dual agonist targeting both GLP-1 and glucagon receptors for synergistic metabolic effects.
Clinical Results
Phase 2 trials showed up to 18.7% body weight reduction at 46 weeks.
Research Benefits
- Significant weight reduction
- Improved liver health (NASH)
- Enhanced insulin sensitivity
- Cardiovascular benefits
Mechanism
The glucagon component increases energy expenditure while GLP-1 reduces appetite.
Research-grade peptides contain only the active ingredient and are NOT equivalent to FDA-approved pharmaceuticals.